SCHEMBL6997487

SCHEMBL6997487

N#Cc1ccc(OCC(O)CN2CC3CC(C2)CN(C(=O)C(N)=O)C3)cc1

nearest known ligand 0.71

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.49
ALDH1A1 P00352 2/20 0.49
KCNH2 Q12809 1/20 0.48
MEN1 O00255 3/20 0.47
KMT2A Q03164 3/20 0.47
AGER Q15109 1/20 0.43
MAPK1 P28482 2/20 0.41
MAPT P10636 2/20 0.41
POLB P06746 2/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
GRIN1 Q05586 2/20 0.41
GRIN2B Q13224 2/20 0.41
HPGD P15428 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
HSD17B10 Q99714 1/20 0.41
HIF1A Q16665 1/20 0.41
ATM Q13315 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6742821 0.92 KDM4E (0.51) KDM4EALDH1A1KCNH2MEN1KMT2A
SCHEMBL6619543 0.88 MEN1 (0.53) KDM4EALDH1A1KCNH2MEN1KMT2A
SCHEMBL6622630 0.88 MEN1 (0.53) KDM4EALDH1A1KCNH2MEN1KMT2A
SCHEMBL6993777 0.88 KDM4E (0.60) KDM4EALDH1A1KCNH2MEN1KMT2A
SCHEMBL7032087 0.88 KDM4E (0.60) KDM4EALDH1A1KCNH2MEN1KMT2A
SCHEMBL6993770 0.88 KDM4E (0.60) KDM4EALDH1A1KCNH2MEN1KMT2A
SCHEMBL7032100 0.88 KDM4E (0.60) KDM4EALDH1A1KCNH2MEN1KMT2A
SCHEMBL6992335 0.85 KCNH2 (0.50) KDM4EALDH1A1KCNH2MEN1KMT2A
SCHEMBL6992337 0.85 KCNH2 (0.50) KDM4EALDH1A1KCNH2MEN1KMT2A
SCHEMBL6618869 0.85 KCNH2 (0.52) KDM4EALDH1A1KCNH2MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030212095-A1 New bispidine compounds and their use in the treatment of cardiac arrhythmias ASTRAZENECA AB (SE) 2003-11-13 US disclosed
EP-1301510-A1 NEW BISPIDINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF CARDIAC ARRHYTHMIAS AstraZeneca AB (SE) 2003-04-16 EP disclosed
WO-2002004446-A1 NEW BISPIDINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF CARDIAC ARRHYTHMIAS ASTRAZENECA AB (SE) 2002-01-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030212095-A1 New bispidine compounds and their use in the treatment of cardiac arrhythmias KCNH1, LBR, CACNA1E KDM4E 4058/4885ALDH1A1 892/4885KCNH2 7/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.